Results 1 to 10 of about 986 (133)

Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine–Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions [PDF]

Pharmaceutics
Background: Fluoxetine, a widely prescribed selective serotonin reuptake inhibitor, exhibits significant interindividual variability in pharmacokinetics, largely attributed to pharmacogenomic factors. Objectives: The study aimed to evaluate the impact of
Carla González de la Cruz, Levin Thomas, Carmen Mata-Martín, Idian González, Adrián LLerena, Eva M. Peñas-Lledó   +5 more
doaj   +2 more sources

Effects of norfluoxetine and venlafaxine in zebrafish larvae: Molecular data

Data in Brief, 2020
The data presented herein relates to the article entitled “Norfluoxetine and venlafaxine in zebrafish larvae: single and combined toxicity of two pharmaceutical products relevant for risk assessment” [1].
Pedro Rodrigues, Virgínia Cunha, Luís Oliva-Teles, Marta Ferreira, Laura Guimarães   +4 more
doaj   +3 more sources

Bridging Literature and Real-World Evidence: External Evaluation and Development of Fluoxetine Population Pharmacokinetics Model [PDF]

Pharmaceutics
Background: Fluoxetine is widely prescribed to treat depression but exhibits high inter-individual and inter-ethnic pharmacokinetic (PK) variability. Most published population pharmacokinetic (PopPK) models were derived from Western patients, and their ...
Bing Han, Nuo Xu, Chen Ma, Gehang Ju, Xie Xi, Cheng Qian, Nan Guo, Xin Liu, Xiao Zhu, Cong Li, Li Liu   +10 more
doaj   +2 more sources

Detecting fluoxetine and norfluoxetine in wild bird tissues and feathers [PDF]

Environment International, 2019
The contamination of the environment with human pharmaceuticals is widespread and demand for such products is mounting globally. Wild vertebrates may be at particular risk from any effects from pharmaceuticals, because of the evolutionary conservation of
Sophia E. Whitlock, M. Glória Pereira, Julie Lane, Darren Sleep, Richard F. Shore, Kathryn E. Arnold   +5 more
doaj   +5 more sources

Distribution and excretion of fluoxetine and norfluoxetine in human milk [PDF]

British Journal of Clinical Pharmacology, 1999
Aims To characterize milk/plasma (M/P) ratio and infant dose, for fluoxetine and norfluoxetine, in breast‐feeding women taking fluoxetine for the treatment of depression, and to determine the plasma concentration of these drugs in their infants.
J H Kristensen, Kenneth F Ilett, L Peter Hackett   +2 more
exaly   +3 more sources

Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders

Pharmacology Research and Perspectives, 2021
Over the last few years, fluoxetine has been one of the most prescribed medications for the treatment of diverse psychiatric conditions in Mexico.
Julia Sagahón-Azúa, Susanna Edith Medellín-Garibay, Rosa Del Carmen Milán-Segovia   +2 more
exaly   +2 more sources

Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain [PDF]

Neuropsychopharmacology, 1993
Like fluoxetine, the N-demethylated metabolite norfluoxetine exists in R- and S-enantiomeric forms. S-Norfluoxetine inhibited serotonin (5-HT) uptake and [3H]paroxetine binding to 5-HT uptake sites with a pKi of 7.86 and 8.88 or 14 and 1.3 nM, respectively, whereas R-norfluoxetine was 22 and 20 times, respectively, less potent.
David T Wong, Frank P Bymaster, Leroy R Reid   +2 more
exaly   +3 more sources

Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers [PDF]

Pharmaceutics
Background/Objectives: Fluoxetine (FLX) is the inhibitor of serotonin reuptake most prescribed in pregnant women with depression. This study evaluates the influence of gestational diabetes mellitus (GDM) on the enantioselective pharmacokinetics and ...
Daniela Miarelli Carvalho, Glauco Henrique Balthazar Nardotto, Gabriela Campos de Oliveira Filgueira, Geraldo Duarte, Ricardo Carvalho Cavalli, Vera Lucia Lanchote, Elaine Christine Dantas Moisés   +6 more
doaj   +2 more sources

Case Report: Targeted treatment by fluoxetine/norfluoxetine of a KCNC2 variant causing developmental and epileptic encephalopathy [PDF]

Frontiers in Pharmacology
The Kv3.2 subfamily of voltage activated potassium channels encoded by the KCNC2 gene is abundantly expressed in neurons that fire trains of fast action potentials that are a major source of cortical inhibition.
Ping Li, Alice Butler, Yu Zhou, Karl L. Magleby, Christina A. Gurnett, Lawrence Salkoff   +5 more
doaj   +2 more sources

Predicting drug–drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling [PDF]

Frontiers in Molecular Biosciences
IntroductionAyahuasca is a psychedelic preparation containing N,N-dimethyltryptamine (DMT) and the β-carboline harmine (HRM), a reversible monoamine oxidase A inhibitor that enables DMT oral bioavailability.
Gabriella de Souza Gomes Ribeiro, Beatriz Aparecida Passos Bismara Paranhos, Fabiane Dörr, Maurício Yonamine, Bianca Villanova, Lorena Terene Lopes Guerra, Adrieli Oliveira Raminelli, Jose Augusto Silva Reis, Caio Cesar de Paula, Anna Beatriz Vicentini Zacharias, Jaime Eduardo Cecílio Hallak, Jaime Eduardo Cecílio Hallak, Rafael Guimarães dos Santos, Rafael Guimarães dos Santos, Frederico Severino Martins, Tania Marcourakis   +15 more
doaj   +2 more sources